




RealRate

# PHARMACEUTICAL 2023

Sonnet BioTherapeutics Holdings Inc.  
Rank 441 of 446





RealRate

# PHARMACEUTICAL 2023

## Sonnet BioTherapeutics Holdings Inc. Rank 441 of 446



The relative strengths and weaknesses of Sonnet BioTherapeutics Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonnet BioTherapeutics Holdings Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 43% points. The greatest weakness of Sonnet BioTherapeutics Holdings Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 328% points.

The company's Economic Capital Ratio, given in the ranking table, is -480%, being 523% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	5,414
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,165
Liabilities, Non-Current	204
Other Assets	370
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-52
Other Revenues	350
Property and Equipment	46
Research and Development	21,444
Selling, General and Administrative Expense	8,575

Output Variable	Value in 1000 USD
Assets	5,830
Liabilities	8,369
Expenses	30,019
Revenues	350
Stockholders Equity	-2,539
Net Income	-29,722
Comprehensive Net Income	-29,722
Economic Capital Ratio	-480%